Intellectia LogoIntellectia
Product
Resources
Markets
News
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
NewsPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GYRE
stocks logo

GYRE

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
4 Analyst Rating
up Image0
Wall Street analysts forecast GYRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GYRE is 24.25 USD with a low forecast of 20.00 USD and a high forecast of 28.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 6.920
sliders
Low
20.00
Averages
24.25
High
28.00
up Image0
Current: 6.920
sliders
Low
20.00
Averages
24.25
High
28.00
See All Ratings
No Data

Valuation Metrics

The current forward P/E ratio for Gyre Therapeutics Inc (GYRE.O) is 0.00, compared to its 5-year average forward P/E of 6.05. For a more detailed relative valuation and DCF analysis to assess Gyre Therapeutics Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
6.05
Current PE
0.00
Overvalued PE
26.22
Undervalued PE
-14.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.59
Current PS
0.00
Overvalued PS
2.53
Undervalued PS
-1.34

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

GYRE News & Events

Events Timeline

(ET)
2025-06-10
07:08:05
Gyre Therapeutics announces first doing in Phase 1 trial of F230
select
2025-05-22 (ET)
2025-05-22
23:55:59
Gyre Therapeutics 2.22M share Spot Secondary priced at $9.00
select
2025-05-22
16:17:54
Gyre Therapeutics announces Hydronidone trial met primary endpoint
select
Sign Up For More Events
Sign Up For More Events

News

Preview
9.0
06-10Newsfilter
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

  • Clinical Trial Announcement: Gyre Therapeutics has successfully dosed its first volunteer in a Phase 1 clinical trial for F230, an endothelin A receptor antagonist aimed at treating pulmonary arterial hypertension (PAH), marking the company's entry into this high-mortality cardiovascular field.

  • Market Potential and Pipeline Expansion: The PAH market in China is projected to grow significantly, and Gyre is expanding its pipeline with F230 alongside its lead candidate Hydronidone, which is set for a New Drug Application submission later this year.

Preview
2.0
05-27Benzinga
MAC Copper, ATS, Pony AI And Other Big Stocks Moving Higher On Tuesday

  • U.S. Stock Market Performance: U.S. stocks rose significantly, with the Dow Jones gaining around 500 points on Tuesday, driven by notable increases in various companies' shares, including MAC Copper Limited and E2open Parent Holdings, following acquisition announcements.

  • Notable Stock Gains: Several companies experienced substantial stock price increases, such as Gyre Therapeutics (23% rise), ATS Corporation (22.3% rise), and CoreWeave (17.7% rise), reflecting positive market sentiment and corporate developments.

Preview
2.0
05-23Benzinga
Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session

  • Stock Market Overview: U.S. stock futures are slightly lower, with notable declines in pre-market trading for several companies, including Ross Stores, which fell 11.2% after issuing disappointing second-quarter earnings guidance despite beating quarterly earnings and revenue estimates.

  • Other Notable Stock Movements: Several other companies also experienced significant drops in pre-market trading, such as Deckers Outdoor Corporation (-16%), Bicara Therapeutics Inc (-20.2%), and Workday, Inc. (-6.5%), following various disappointing financial announcements or forecasts.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Gyre Therapeutics Inc (GYRE) stock price today?

The current price of GYRE is 6.92 USD — it has decreased -1.42 % in the last trading day.

arrow icon

What is Gyre Therapeutics Inc (GYRE)'s business?

Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.

arrow icon

What is the price predicton of GYRE Stock?

Wall Street analysts forecast GYRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GYRE is 24.25 USD with a low forecast of 20.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Gyre Therapeutics Inc (GYRE)'s revenue for the last quarter?

Gyre Therapeutics Inc revenue for the last quarter amounts to 22.06M USD, decreased -18.82 % YoY.

arrow icon

What is Gyre Therapeutics Inc (GYRE)'s earnings per share (EPS) for the last quarter?

Gyre Therapeutics Inc. EPS for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Gyre Therapeutics Inc (GYRE)'s fundamentals?

The market is revising No Change the revenue expectations for Gyre Therapeutics, Inc. (GYRE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -20.55%.
arrow icon

How many employees does Gyre Therapeutics Inc (GYRE). have?

Gyre Therapeutics Inc (GYRE) has 574 emplpoyees as of August 06 2025.

arrow icon

What is Gyre Therapeutics Inc (GYRE) market cap?

Today GYRE has the market capitalization of 609.66M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free